Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0WF7K
|
|||
| Former ID |
DAP001145
|
|||
| Drug Name |
Candoxatril
|
|||
| Synonyms |
UK 79300; Candoxatril [USAN:INN:BAN]; UK-79,300; Candoxatril (JAN/USAN/INN); Cyclohexanecarboxylic acid, 4-(((1-(2-carboxy-3-(2-methoxyethoxy)propyl)cyclopentyl)carbonyl)-amino)-, (4(S)-cis); [4(S)-cis]-4-[[[1-[3-[(2,3-dihydro-1H-indeb5-yl)oxy]-2-[(2-methoxyethoxy)methyl]-3-oxopropyl]cyclopentyl]carbonyl]amino]cyclohexanecarboxylic acid; Cis-4-{[(1-{(2S)-3-(2,3-dihydro-1H-inden-5-yloxy)-2-[(2-methoxyethoxy)methyl]-3-oxopropyl}cyclopentyl)carbonyl]amino}cyclohexanecarboxylic acid; (alphaS)-1-((cis-4-Carboxycyclohexyl)carbamoyl)-alpha-((2-methoxyethoxy)methyl)cyclopentanepropionic acid; 3-(1-((4-Carboxycyclohexyl)carbamoyl)cyclopentyl)-2-(2-methoxyethoxymethyl)propanoic acid 5-indanyl ester; 4-[[1-[(2S)-3-(2,3-dihydro-1H-inden-5-yloxy)-2-(2-methoxyethoxymethyl)-3-oxopropyl]cyclopentanecarbonyl]amino]cyclohexane-1-carboxylic acid; 4-[[1-[3-(2,3-dihydro-1H-inden-5-yloxy)-2-(2-methoxyethoxymethyl)-3-oxopropyl]cyclopentanecarbonyl]amino]cyclohexane-1-carboxylic acid
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hypertension [ICD-11: BA00-BA04; ICD-9: 401] | Phase 3 | [1], [2] | |
| Therapeutic Class |
Antihypertensive Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C29H41NO7
|
|||
| Canonical SMILES |
COCCOCC(CC1(CCCC1)C(=O)NC2CCC(CC2)C(=O)O)C(=O)OC3=CC4=C(CCC4)C=C3
|
|||
| InChI |
1S/C29H41NO7/c1-35-15-16-36-19-23(27(33)37-25-12-9-20-5-4-6-22(20)17-25)18-29(13-2-3-14-29)28(34)30-24-10-7-21(8-11-24)26(31)32/h9,12,17,21,23-24H,2-8,10-11,13-16,18-19H2,1H3,(H,30,34)(H,31,32)/t21?,23-,24?/m0/s1
|
|||
| InChIKey |
ZTWZVMIYIIVABD-RZMWZJFBSA-N
|
|||
| CAS Number |
CAS 123122-55-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| ChEBI ID |
CHEBI:3353
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Neutral endopeptidase (MME) | Target Info | Inhibitor | [3], [4] |
| KEGG Pathway | Renin-angiotensin system | |||
| Hematopoietic cell lineage | ||||
| Protein digestion and absorption | ||||
| Alzheimer's disease | ||||
| NetPath Pathway | EGFR1 Signaling Pathway | |||
| TGF_beta_Receptor Signaling Pathway | ||||
| Reactome | Metabolism of Angiotensinogen to Angiotensins | |||
| WikiPathways | Metabolism of Angiotensinogen to Angiotensins | |||
| Primary Focal Segmental Glomerulosclerosis FSGS | ||||
| Alzheimers Disease | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6492). | |||
| REF 2 | Drug information of Candoxatril, 2008. eduDrugs. | |||
| REF 3 | Neutral endopeptidase inhibitor suppresses the early phase of atrial electrical remodeling in a canine rapid atrial pacing model. Indian Pacing Electrophysiol J. 2008 Apr 1;8(2):102-13. | |||
| REF 4 | Dual inhibition of angiotensin converting enzyme and neutral endopeptidase produces effective blood pressure control in spontaneously hypertensive rats. Bratisl Lek Listy. 2005;106(12):407-11. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.